Fennec Pharmaceuticals (TSE:FRX) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$9.08 and traded as high as C$10.14. Fennec Pharmaceuticals shares last traded at C$10.14, with a volume of 1,834 shares changing hands.

Analyst Ratings Changes

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Stock Performance

The firm’s 50-day moving average is C$9.11 and its 200 day moving average is C$7.82. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. The stock has a market cap of C$195.55 million, a PE ratio of -171.77 and a beta of 0.25.

Insider Buying and Selling

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of C$8.76, for a total value of C$87,552.00. In the last 90 days, insiders have sold 13,617 shares of company stock valued at $122,514. Insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.